In organophosphate poisoning, when is activated charcoal indicated, what is the recommended dose, and what are the contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Activated charcoal in organophosphate poisoning

Activated charcoal is reasonable only if given early (ideally within 1 hour, consider up to 2–4 hours if large ingestion and GI motility intact) at a single dose of 1 g/kg (adult max 50–100 g), and it is contraindicated if the airway is unprotected or bowel obstruction is suspected. 1, 2

  • Indication (time- and risk-based)

    • Give single-dose activated charcoal (SDAC) when:
      • Potentially toxic oral organophosphate ingestion AND presentation within 1 hour. This timing offers the greatest absorption reduction and the only plausible chance to affect outcomes tied to morbidity/mortality/QOL, despite no proven clinical outcome benefit in trials 1, 2.
      • Consider SDAC up to 2–4 hours post-ingestion if:
        • Large ingestion, delayed gastric emptying, or sustained/slow-release formulations, and patient is stable with intact/protected airway. Although volunteer data show diminishing benefit after 1 hour, some benefit cannot be excluded; prioritize safety and airway first 1, 2.
    • Not routine beyond 4 hours, given rapidly declining efficacy and lack of outcome benefit data. Prioritize proven mortality/morbidity interventions (airway/ventilation, atropine, pralidoxime) 1, 2, 3.
  • Dose and administration

    • Adults: 50–100 g orally/NG as a single dose (or 1 g/kg if weight-based). Children: 1 g/kg (typical max 50 g) 4, 1, 2.
    • Avoid cathartics (e.g., sorbitol), especially in children, due to risks of dehydration/electrolyte derangements and no outcome benefit; repeated charcoal with sorbitol has caused fatal hypernatremic dehydration 4, 5.
    • Multidose activated charcoal is not indicated for organophosphates (no evidence of improved morbidity/mortality; reserve for specific agents like carbamazepine, theophylline, etc.) 5.
  • Contraindications and caveats

    • Absolute: Unprotected or absent airway reflexes (unless intubated), risk of aspiration; suspected/known GI obstruction or perforation 1, 2, 5.
    • Relative: Intractable vomiting, hemodynamic instability precluding safe administration; co-ingestants not adsorbed by charcoal (not typical for OPs) 4, 1.
    • Do not delay antidotes or airway interventions to give charcoal. Mortality benefit comes from prompt atropine, pralidoxime, and ventilatory support; charcoal has no proven outcome benefit in OP poisoning and must not interfere with definitive therapy 3, 1, 6.
  • Evidence nuance (why this recommendation)

    • Highest-quality consensus statements on SDAC show no demonstrated improvement in clinical outcomes; benefit is time-dependent and greatest within 1 hour, with uncertain benefit thereafter 1, 2.
    • An OP-specific retrospective study found no improvement in mortality, respiratory failure, or ventilation duration with charcoal-sorbitol vs no charcoal, reinforcing that charcoal must never delay life-saving therapies 6.
    • Current poisoning guidelines emphasize antidotal therapy (atropine, oximes) for organophosphates; use charcoal only as early adjunct decontamination when safe 3.
  • Practical algorithm

    • If suspected OP ingestion:
      1. Secure airway/oxygenation; intubate if needed.
      2. Start atropine immediately; add pralidoxime per dosing guidance 3.
      3. Consider SDAC 1 g/kg (max 50–100 g) if:
        • Ingestion ≤1 hour (strongest rationale), or up to 2–4 hours if large ingestion/slow GI transit,
        • Airway is intact or protected,
        • No bowel obstruction/perforation.
      4. Avoid sorbitol and multidose charcoal.
      5. Monitor for aspiration; stop if vomiting or deterioration.
  • Common pitfalls to avoid

    • Giving charcoal before securing a compromised airway → aspiration pneumonia and worse outcomes 1, 2.
    • Delaying atropine/oximes or ventilation to administer charcoal → increases mortality 3.
    • Routine use beyond 1 hour without clear rationale, or using multidose regimens in OP poisoning → no proven benefit, added risk 1, 2, 5.

Related Questions

In which oral poisonings is activated charcoal mandatory, contraindicated, or only partially effective; what factors diminish its efficacy; what adverse events can occur if administered inappropriately; and are there any non‑oral poisonings where activated charcoal is useful?
In an alert, non-intubated patient who has ingested a toxin, should activated charcoal be administered?
Can activated charcoal be given in opioid (opiate) poisoning?
Should activated charcoal be avoided in patients who have already been intubated?
Why is activated charcoal contraindicated in patients with an unprotected airway (e.g., unconscious, GCS < 8, seizing, intoxicated, or unable to maintain protective reflexes)?
What are the clinical indications for Norflox‑TZ (norfloxacin and tinidazole)?
What can I take to treat hypotension caused by my clonidine and propranolol medication?
Should aspirin and clopidogrel be administered as loading doses within the first two hours of a minor ischemic stroke or high‑risk transient ischemic attack?
A 47-year-old obese patient with type 2 diabetes mellitus, baseline weight 120 kg, started on tirzepatide (Mounjaro) 2.5 mg then increased to 5 mg and maintained for 6–7 weeks, also taking dapagliflozin and metformin. At week 6 his weight was 113 kg, but over the past two weeks he reports paradoxical increased hunger, lethargy, and a weight plateau while still on 5 mg tirzepatide. What steps should be taken?
Are there age-related considerations for administering loading doses of aspirin and clopidogrel in patients with minor ischemic stroke or high-risk TIA?
What is the appropriate treatment for a patient with a serum uric acid level of 9.8 mg/dL, no gouty joint symptoms, and a uric‑acid kidney stone?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.